

WHAT IS CLAIMED IS:

1. A tumor cell transfected with a DNA coding for at least one MHC class II ligand.
2. The tumor cell of claim 1, wherein said at least one MHC class II ligand is selected from the group consisting of CD4, LAG-3, and derivatives thereof.
3. A process for preparing the tumor cell of claim 1, comprising:
 - removing tumor cells from a patient;
 - transfecting a tumor cell with a DNA coding for at least one MHC class II ligand; and
 - recovering the transfected tumor cell.
4. The process of claim 3, wherein said at least one MHC class II ligand is selected from the group consisting of CD4, LAG-3, and derivatives thereof.
5. A process for preparing cells transfected with a DNA coding for at least one MHC class II ligand, comprising:
 - removing cells from a patient;
 - transfecting said cells with a DNA coding for at least one MHC class II ligand; and
 - recovering the transfected cells.
6. The process of claim 5, wherein said at least one MHC class II ligand is selected from the group consisting of CD4, LAG-3, and derivatives thereof.

20041600-011002

7. A pharmaceutical composition for treating or preventing pathological conditions involving an antigen specific immune response, comprising a pharmaceutically acceptable vehicle and cells transfected with DNA coding for at least one MHC class II ligand and expressing said at least one MHC class II ligand.

8. The pharmaceutical composition of claim 7, wherein said at least one MHC class II ligand is selected from the group consisting of CD4 and LAG-3.

9. A method for treating or preventing a pathological condition involving antigen specific T-cell mediated immune response, comprising administering the pharmaceutical composition of claim 7 to a subject in need thereof.

10044500-01000